Fortrea Holdings FTRE
NASDAQ FTRE
$18.16 -0.46 (-2.47%)
As of: Sep 4, 2026 · 1:30 PM EDT

Fortrea Holdings (FTRE) Cash from Financing Activities (2022 - 2025)

Fortrea Holdings' (FTRE) quarterly Cash from Financing Activities came in at -$75.7 million in Q4 2025, down 6781.82% YoY from $1.1 million in Q4 2024, and down 51.4% on a QoQ basis from -$50.0 million in Q3 2025.

Analysis

Fortrea Holdings (FTRE) Cash from Financing Activities (2022 - 2025) Analysis & Trends

Fortrea Holdings (FTRE) has 4 years of Cash from Financing Activities data on file, last reported at -$75.7 million in Q4 2025.

  • Quarterly Cash from Financing Activities fell 6781.82% year-over-year to -$75.7 million in Q4 2025, while the trailing twelve-month figure through Jun 2026 was -$125.7 million (down 466.47% YoY) and the FY2025 annual result came in at -$76.3 million, up 84.67% from the prior year.
  • Cash from Financing Activities slipped to -$75.7 million in Q4 2025, from -$50.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $88.4 million in Q1 2025 to a low of -$504.0 million in Q2 2024.
  • A 4-year average of -$54.8 million and a median of -$10.8 million in 2023 frame the typical range for Cash from Financing Activities.
  • The widest YoY moves for Cash from Financing Activities: up 315.02% in 2025, down 6781.82% in 2025.
  • Tracing FTRE's Cash from Financing Activities over 4 years: stood at -$5.9 million in 2022, then tumbled by 30.51% to -$7.7 million in 2023, then jumped by 85.71% to -$1.1 million in 2024, then tumbled by 6781.82% to -$75.7 million in 2025.
  • The last three Cash from Financing Activities figures came in at -$75.7 million (Q4 2025), -$50.0 million (Q3 2025), and -$39.0 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - 2.42 Bn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - -273.15 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 27.18 Mn
10 Fortrea Holdings 1.72 Bn 1.55 Bn 139.20 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -75.70 Mn
Sep 30, 2025 -50.00 Mn
Jun 30, 2025 -39.00 Mn
Mar 31, 2025 88.40 Mn
Dec 31, 2024 -1.10 Mn
Sep 30, 2024 -14.00 Mn
Jun 30, 2024 -504.00 Mn
Mar 31, 2024 21.30 Mn
Dec 31, 2023 -7.70 Mn
Sep 30, 2023 -7.70 Mn
Jun 30, 2023 -149.90 Mn
Mar 31, 2023 24.50 Mn
Dec 31, 2022 -5.90 Mn
Sep 30, 2022 -46.50 Mn